logo
Updated

AuthorUp for Grabs

Want to improve the page's content? Try to propose a change.

Amy Nham, PharmD1,2; Taylor Holly, MPH2; John Flores, MD2,3; David Kern2; Irina Tabidze, MD2 (

Summary

What is already known about this topic?

High rates of syphilis and HIV coinfection occur among gay, bisexual, and other men who have sex with men (MSM). Neurosyphilis, ocular syphilis, and otic syphilis (NOO syphilis) can occur at any syphilis stage with or without HIV coinfection.

What is added by this report?

During January 1–October 31, 2023, 40 NOO syphilis cases were reported in Chicago, 67.5% of which occurred in persons without HIV infection compared with 43.8% in 2019. Among 33 (82.5%) NOO syphilis patients whose sex and that of their sexual partners were reported, 18 (54.5%) were not MSM compared with four of 15 patients (26.7%) in 2019.

What are the implications for public health practice?

Clinicians should consider NOO syphilis even in persons who do not have HIV and who are not MSM.

Related Materials

The incidence of syphilis, a sexually transmitted infection caused by the bacterium Treponema pallidum, has been increasing in the United States since 2001.* Neurosyphilis, ocular syphilis, and otic syphilis (NOO syphilis), caused by T. pallidum invading the central nervous system, eyes, and ears, respectively, can occur in the primary, secondary, latent, or tertiary† stages of syphilis. NOO syphilis manifestations are often debilitating and can include meningitis, stroke, motor or sensory deficits, blindness, and hearing loss.

Data from the early to mid-2000s suggested that NOO syphilis was more commonly identified among gay, bisexual, and other men who have sex with men (MSM) and persons with HIV, likely reflecting the syphilis trends at the time these data were collected (1–3). Data collected from Chicago in 2019 showed that 11 of 16 NOO syphilis cases were diagnosed in MSM, and nine cases in persons with HIV. In 2023, health care providers in Chicago reported an increase in NOO syphilis among heterosexual persons without HIV. To assess whether this increase was consistent citywide, this analysis characterized NOO syphilis cases stratified by HIV status to identify factors associated with diagnosis in Chicago during January 1–October 31, 2023.

Data Collection and Analyses

Surveillance data reported to the Chicago Department of Public Health (CDPH) were analyzed to describe NOO syphilis cases diagnosed in 2023. CDPH queried the Chicago Health Information Management System (CHIMS) to identify potential NOO syphilis cases based on 1) cerebrospinal fluid (CSF) test results indicative of neurosyphilis, including reactive CSF Venereal Disease Research Laboratory (VDRL), elevated CSF protein, and elevated CSF leukocyte count, 2) treatment with intravenous penicillin, or 3) any documented NOO syphilis sign or symptom in a Chicago resident during January 1–October 31, 2023. (4). CDPH abstracted clinical information from medical records to identify cases that met the 2018 Council of State and Territorial Epidemiologists’ verified, likely, or possible case definitions for NOO syphilis (4). CDPH matched cases identified from CHIMS to the Enhanced HIV/AIDS Reporting System to obtain data on HIV status and treatment (5). Data from the National Electronic Telecommunications System for Surveillance were used to obtain 2019 case data for comparison, excluding COVID-19 pandemic years in which cases were likely underreported. This activity was reviewed by CDC, deemed not research, and was conducted consistent with applicable federal law and CDC policy.§

Outcomes

During January 1–October 31, 2023, a total of 2,611 cases of syphilis (all stages) were reported to CDPH; 689 (26.4%) were among persons with HIV, and 521 (20.0%) were among MSM. Among all 2,611 cases, 40 (1.5%) NOO syphilis cases were reported, including 14 in patients who had more than one type of NOO syphilis (

Among 28 (70.0%) persons for whom signs or symptoms were reported, decreased vision (60.7%), rash (35.7%), and acute headache (32.1%) were the most commonly reported. Among 14 (35.0%) persons whose signs and symptoms were consistent with primary or secondary syphilis, eight had abnormal CSF tests. Signs and symptoms of NOO syphilis were similar in persons who did and did not have HIV.

Preliminary Conclusions and Actions

During January 1–October 31, 2023, NOO syphilis cases in Chicago were identified more frequently in persons who did not have HIV and who were not MSM compared with cases identified in 2019. Clinicians should consider NOO syphilis even in persons who do not have HIV and who are not MSM. Enhanced surveillance efforts to better understand NOO syphilis trends are needed.

Acknowledgments

Suzanne Beavers, Lisa Varella, CDC; Katherine Boss, Donna Peace, Kathleen Ritger, Eli Schulman, Divina B. Vargas, Michael Wasz, Chicago Department of Public Health; Syphilis Disease Intervention Specialists, Chicago Department of Public Health Syndemic Infectious Disease Bureau.

Corresponding author: Amy Nham, ovp8@cdc.gov.

1Epidemic Intelligence Service, CDC; 2Chicago Department of Public Health, Chicago, Illinois; 3University of Chicago Medicine, Chicago, Illinois.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. David Kern reports partial meeting travel support from the National Alliance of State and Territorial AIDS Directors. No other potential conflicts of interest were disclosed.

https://www.cdc.gov/syphilis/about/index.html

§ 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.

References

CharacteristicNo. (column %)
2019 †January 1–October 31, 2023
Total N = 16 †Total N = 40Persons with HIV n = 13Persons without HIV n = 27
Type of syphilis
Neurosyphilis28 (70.0)
Ocular syphilis24 (60.0)
Otic syphilis2 (5.0)
More than one type of NOO syphilis14 (35.0)
Age group, yrs
20–296 (37.5)8 (20.0)2 (15.4)6 (22.2)
30–396 (37.5)7 (17.5)3 (23.1)4 (14.8)
40–493 (18.8)6 (15.0)4 (30.8)2 (7.4)
50–591 (6.3)8 (20.0)2 (15.4)6 (22.2)
≥600 (—)11 (27.5)2 (15.4)9 (33.3)
Median age, yrs (range)33 (21–52)46.5 (23–82)43 (29–66)52 (23–82)
Sex
Female2 (12.5)11 (27.5)0 (—)11 (40.7)
Male14 (87.5)29 (72.5)13 (100)16 (59.3)
Race and ethnicity §
Asian or Pacific Islander1 (6.3)1 (2.5)1 (7.7)0 (—)
Black or African American5 (31.3)26 (65.0)9 (69.2)17 (63.0)
White9 (56.3)7 (17.5)1 (7.7)6 (22.2)
Hispanic or Latino1 (6.3)6 (15.0)2 (15.4)4 (14.8)
MSM status
MSM11 (68.8)15 (37.5)10 (76.9)5 (18.5)
Non-MSM4 (25.0)18 (45.0)2 (15.4)16 (59.3)
Unknown1 (6.3)7 (17.5)1 (7.7)6 (22.2)
HIV status
Positive9 (56.3)13 (32.5)13 (100)0 (—)
Negative7 (43.8)27 (67.5)0 (—)27 (100)
Previous syphilis diagnosis
Yes14 (35.0)6 (46.2)8 (29.6)
No21 (52.5)6 (46.2)15 (55.6)
Unknown5 (12.5)1 (7.7)4 (14.8)
NOO syphilis treatment received
Yes36 (90.0)11 (84.6)25 (92.6)
No4 (10.0)2 (15.4)2 (7.4)
Admitted to hospital
Yes23 (57.5)9 (69.2)14 (51.9)
No5 (12.5)0 (—)5 (18.5)
Unknown12 (30.0)4 (30.8)8 (29.6)
Sign or symptom ¶
Acute headache9 (22.5)5 (38.5)4 (14.8)
Central nervous system deficits4 (10.0)3 (23.1)1 (3.7)
Decreased vision17 (42.5)4 (30.8)13 (48.1)
Fever3 (7.5)2 (15.4)1 (3.7)
Gait difficulty8 (20.0)3 (23.1)5 (18.5)
Hearing loss2 (5.0)0 (—)2 (7.4)
Lymphadenopathy1 (2.5)1 (7.7)0 (—)
Malaise3 (7.5)2 (15.4)1 (3.7)
Meningismus1 (2.5)0 (—)1 (3.7)
Optic neuritis3 (7.5)2 (15.4)1 (3.7)
Photophobia6 (15.0)1 (7.7)5 (18.5)
Rash10 (25.0)2 (15.4)8 (29.6)
Retinitis6 (15.0)2 (15.4)4 (14.8)
Sensory change5 (12.5)1 (7.7)4 (14.8)
Ulcer or lesion6 (15.0)2 (15.4)4 (14.8)
Uveitis7 (17.5)2 (15.4)5 (18.5)
Weakness7 (17.5)4 (30.8)3 (11.1)
Undetectable HIV viral load**
YesNA7 (53.8)NA
NoNA6 (46.2)NA
CD4 †† §§
YesNA4 (30.8)NA
NoNA9 (69.2)NA
On HIV antiretroviral therapy ¶¶
YesNA8 (61.5)NA
NoNA2 (15.4)NA
UnknownNA3 (23.1)NA

Abbreviations: MSM = men who have sex with men; NA = not applicable; NOO = neuro-, ocular, and otic.

  • As of November 6, 2023.
    † Data not available for all variables in 2019.
    § Persons of Hispanic or Latino (Hispanic) origin might be of any race but are categorized as Hispanic; all racial groups are non-Hispanic.
    ¶ Signs and symptoms are not mutually exclusive.
    ** Most recent viral load test result in 2023 was †† CD4 is a class of helper T-lymphocytes.
    §§ Most recent CD4 count in 2023 was μL.
    ¶¶ Documentation of HIV antiretroviral therapy in previous 12 months.

Where this page came from

This page was imported from Centers for Disease Control and Prevention. Material produced by the Centers for Disease Control and Prevention is a work of the United States government and is in the public domain.

Nobody has written it yet — it is the source material at a new address, which is why search engines are asked to skip it and why no one earns from it. It is up for grabs: take it on, and it is yours to rewrite and to earn from.

Licence: CC0 1.0 (public domain) · Adapted from www.cdc.gov

1

0

0

0

Spinner Logo

Comments

Spinner Logo
Version: 1Maintainers: 1Collections: 0CC0 1.0 — public domain
Planetary Nebula
Version: 1Maintainers: 1Collections: 0CC0 1.0 — public domain
Doradus Nebula
Version: 1Maintainers: 1Collections: 0CC0 1.0 — public domain
The Tarantula Nebula
Version: 1Maintainers: 1Collections: 0CC0 1.0 — public domain
Hubble reveals heart of Lagoon Nebula
Version: 1Maintainers: 1Collections: 0CC0 1.0 — public domain
Hubble Images Searchlight Beams from a Preplanetary Nebula
Version: 1Maintainers: 1Collections: 0CC0 1.0 — public domain
Hubble View of a Nitrogen-Rich Nebula